Related Experiment Video

Updated: Mar 13, 2026

Development of Recombinant Proteins to Treat Chronic Pain
10:37

Development of Recombinant Proteins to Treat Chronic Pain

Published on: April 11, 2018

10.0K

Tocilizumab in the treatment of systemic juvenile idiopathic arthritis

Miho Murakami1, Minako Tomiita2, Norihiro Nishimoto1

  • 1Laboratory of Immune Regulation, Wakayama Medical University, Wakayama.

Open Access Rheumatology : Research and Reviews
|July 4, 2012
PubMed

Insights

Tocilizumab effectively treats systemic juvenile idiopathic arthritis by targeting interleukin-6, a key inflammatory cytokine. This therapy offers a safe and effective option for children with this chronic rheumatic condition.

Area of Science:

  • Rheumatology
  • Pediatrics
  • Immunology

Background:

  • Systemic juvenile idiopathic arthritis (SJIA) is a significant childhood rheumatic disease.
  • SJIA presents with fever, rash, arthritis, and potential complications like macrophage activation syndrome.
  • Interleukin-6 (IL-6) overproduction drives SJIA's systemic inflammation and clinical features.

Approach:

  • Tocilizumab, an anti-IL-6 receptor antibody, was developed to target SJIA's underlying pathology.
  • Clinical studies evaluated the efficacy and safety of tocilizumab in active SJIA patients.
  • Regulatory approvals in Japan, EU, and US confirm tocilizumab's therapeutic value.

Key Points:

  • Tocilizumab targets the interleukin-6 pathway central to SJIA pathogenesis.
  • Clinical trials demonstrate significant efficacy and a favorable safety profile for tocilizumab in SJIA.
  • Early and widespread regulatory approval highlights tocilizumab's importance in pediatric rheumatology.

Conclusions:

  • Tocilizumab is a highly effective treatment for systemic juvenile idiopathic arthritis.
  • Targeting IL-6 with tocilizumab addresses the core inflammatory mechanisms of SJIA.
  • The drug's approval and demonstrated success provide a crucial therapeutic advance for affected children.

Keywords:
antihuman interleukin-6 receptor antibodybiologicssystemic juvenile idiopathic arthritistocilizumab

More Related Videos

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

1.3K
Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity10:10

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity

Published on: November 8, 2016

9.3K

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
631
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
692
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
593
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
884
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
586
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
295